If we apply the breast or gastric IHC scoring system to our non-breast/non-gastric tumor samples, an ERBB2 estimated CN gain of 8 or more (estimated CN ≥ 8) would be equivalent to an IHC3 + score (90% sensitivity and 75% specificity). Here, ERBB2 is linked to gastric neoplasm.